

Table S3. A profile of sequence samples containing IN:M50I alone

Pt. ID ¹	Seq. ID ³	Regimen ²	Sample ⁴	Blood Date ⁶	VL ⁵	Start Date ⁷	End Date ⁸	DOSE	
P1	1	ABC/DTG/LAV	Pre	4/28/17	201353	5/8/17		1 tab	Daily
P2	2	FTC/TFV-DF	Post	6/8/17	50449	12/1/08	1/1/15	100 mg/150 mg	Daily
		RAL				12/1/08	11/1/14	400 mg	BID
	3	DTG	Pre	7/6/17	19832	11/1/14	1/1/15	50 mg	Daily
		ABC/DTG/LAV				1/1/15	5/11/17	300 mg/600 mg/50 r	Daily
	4	ABC/DTG/LAV FTC/TFV-DF DTG	Post	3/28/19	12755	7/10/17 7/10/17 7/10/17	3/3/19 7/10/17 7/10/17	300 mg/600 mg/50 r 100 mg/150 mg	Daily Daily
P3	5	ABC/DTG/LAV	Pre	4/10/19	26508	4/17/19		300 mg/600 mg/50 r	Daily
	6	Never on ART	Pre	9/21/17	2044				
P4	7	BIC/TFV-AF/EM	On	12/11/18	51922	12/3/18		1 tab	Daily
P5	8	Never on ART	Pre	3/14/18	7261				
P6	9	ZDV	On	11/28/17	1207	10/31/01	4/1/02	300 mg	bid
		LAV				10/31/01	4/1/02	150 mg	bid
	10	EFV	Pre	3/27/18	2886	10/31/01	4/1/02	600 mg	At bedtime
		STV				6/7/02	6/1/04	40 mg	bid
	11	NFV	On	6/8/10		6/7/02	6/1/04	1250 mg	bid
P7	12	LPV/r	On	11/28/17	1207	3/13/07	6/8/10	400mg/100mg	BID
		FTC/TFV-DF				3/13/07	3/29/17	200mg/ 300mg	daily
	13	AZV	On	11/28/17	1207	6/8/10	3/29/17	300mg	Daily
		RTV				6/8/10	3/29/17	100mg	Daily
	14	EGV/COB/TAF/FTC	On	11/28/17	1207	3/30/17	6/14/18	1 tablet	Daily
P8*	10	BIC/TFV-AF/FTC	Pre	3/27/18	2886	6/14/18		1 tablet	Daily
	11	EFV/FTC/TVF-DF	Pre	7/24/07	52594	10/28/09		1 tablet	Daily
	12		Pre	11/28/17	3016				
	13		Pre	5/2/18	1502				
	14	ABC/DTG/LAV ABC/DTG/LAV	Pre	11/14/18	1262	2/21/19 1/10/20	10/1/19	1 tablet 1 tablet	Daily Daily

1: Patients ID #

2: Sequence ID

3: Regimens, ABC: abacavir, AZV: Atazanavir, BIC: Bictegravir, COB: Cobicistat, DTG: dolutegravir, EFV: Efavirenz, EGV: Elvitegravir, FTC: Emtricitabine, LAV: lamivudine, LPV/r: Lopinavir/ritonavir, NFV: Nelfinavir, TFV-AF: tenofovir AF, TFV-DF: Tenofovir DF, RAL: Raltegravir, RTV: Ritonavir, STV: Stavudine, ZDV: Zidovudine

4: Status of the blood samples as Pre, Post, or ON therapy when collecting blood

5: Date of blood collection

6: Viral load, HIV RNA copy number (copies/ml)

7: Started date of new therapy

8: End of date of the therapy

*: The patient initially came to the NIAID clinic under the Long Term Non-Progressor protocol and moved to viremic patients under ART from 2019.